document output

SETUP.md

@@ -87,6 +87,210 @@ El archivo `test_document.md` contiene un documento de muestra con:
 
 Puedes usar este contenido para probar la funcionalidad del Research Team.
 
+## 📊 Ejemplo de Salida del Research Team
+
+Cuando proceses un documento médico como el del ejemplo de Daratumumab, el Research Team devuelve una respuesta estructurada con análisis detallado:
+
+```json
+{
+  "detailed_analysis": {
+    "claims_extracted": {
+      "all_claims": [
+        {
+          "id": "claim_1",
+          "text": "Daratumumab is a human monoclonal antibody that targets CD38",
+          "type": "core",
+          "importance_score": 9,
+          "position": 1,
+          "context": "Opening statement defining the drug mechanism"
+        },
+        {
+          "id": "claim_2", 
+          "text": "Clinical studies have demonstrated significant efficacy in treating multiple myeloma patients",
+          "type": "core",
+          "importance_score": 8,
+          "position": 2,
+          "context": "Clinical efficacy statement"
+        },
+        {
+          "id": "claim_3",
+          "text": "The POLLUX study demonstrated that daratumumab in combination with lenalidomide and dexamethasone significantly improved progression-free survival",
+          "type": "supporting",
+          "importance_score": 7,
+          "position": 3,
+          "context": "Specific study evidence"
+        }
+      ],
+      "core_claims": [
+        {
+          "id": "claim_1",
+          "text": "Daratumumab is a human monoclonal antibody that targets CD38",
+          "type": "core",
+          "importance_score": 9,
+          "position": 1,
+          "context": "Opening statement defining the drug mechanism"
+        },
+        {
+          "id": "claim_2",
+          "text": "Clinical studies have demonstrated significant efficacy in treating multiple myeloma patients", 
+          "type": "core",
+          "importance_score": 8,
+          "position": 2,
+          "context": "Clinical efficacy statement"
+        }
+      ],
+      "total_claims_found": 3,
+      "core_claims_count": 2
+    },
+    "anchoring_results": {
+      "detailed_anchoring": [
+        {
+          "claim_id": "claim_1",
+          "claim_text": "Daratumumab is a human monoclonal antibody that targets CD38",
+          "validation_status": "validated",
+          "supporting_evidence": [
+            "CD38 is highly expressed on multiple myeloma cells",
+            "Daratumumab demonstrates potent anti-tumor activity through multiple mechanisms"
+          ],
+          "anchored_references": [
+            {
+              "reference_id": "gs_claim_1_1",
+              "supporting_text": "Daratumumab (DARZALEX) is a human IgG1κ monoclonal antibody that binds specifically to CD38",
+              "relevance_score": 0.95,
+              "section": "Background"
+            }
+          ],
+          "quality_assessment": "High quality evidence from peer-reviewed sources"
+        }
+      ],
+      "claims_with_evidence": [
+        {
+          "claim_id": "claim_1",
+          "claim_text": "Daratumumab is a human monoclonal antibody that targets CD38",
+          "validation_status": "validated",
+          "supporting_evidence": [
+            "CD38 is highly expressed on multiple myeloma cells",
+            "Daratumumab demonstrates potent anti-tumor activity through multiple mechanisms"
+          ],
+          "anchored_references": [
+            {
+              "reference_id": "gs_claim_1_1",
+              "supporting_text": "Daratumumab (DARZALEX) is a human IgG1κ monoclonal antibody that binds specifically to CD38",
+              "relevance_score": 0.95,
+              "section": "Background"
+            }
+          ],
+          "quality_assessment": "High quality evidence from peer-reviewed sources"
+        },
+        {
+          "claim_id": "claim_2",
+          "claim_text": "Clinical studies have demonstrated significant efficacy in treating multiple myeloma patients",
+          "validation_status": "validated",
+          "supporting_evidence": [
+            "Phase III trials showed improved overall response rates",
+            "Significant progression-free survival benefit demonstrated"
+          ],
+          "anchored_references": [
+            {
+              "reference_id": "pm_claim_2_1",
+              "supporting_text": "Daratumumab significantly improved outcomes in relapsed/refractory multiple myeloma",
+              "relevance_score": 0.88,
+              "section": "Results"
+            }
+          ],
+          "quality_assessment": "Strong clinical evidence from randomized controlled trials"
+        }
+      ]
+    },
+    "formatted_references": {
+      "references": [
+        {
+          "id": "gs_claim_1_1",
+          "original": "Research findings about daratumumab mechanism",
+          "formatted": "Multiple Authors et al. Daratumumab mechanism of action in multiple myeloma. Hematol Oncol 2024; 42(3): 145-158.",
+          "changes_applied": "Applied J&J journal article format, added proper author citation",
+          "source_type": "journal",
+          "completion_status": "complete"
+        },
+        {
+          "id": "pm_claim_2_1", 
+          "original": "Clinical efficacy research findings",
+          "formatted": "Clinical Research Team et al. Efficacy of daratumumab in multiple myeloma treatment. Blood Cancer J [Internet]. 2024 Mar 15 [cited 2024 Nov 15]; 14(1): 25. Available from: https://doi.org/10.1038/example",
+          "changes_applied": "Applied J&J journal epub format with DOI",
+          "source_type": "journal",
+          "completion_status": "complete"
+        }
+      ],
+      "reference_details": [
+        {
+          "reference_id": "gs_claim_1_1",
+          "formatted_citation": "Multiple Authors et al. Daratumumab mechanism of action in multiple myeloma. Hematol Oncol 2024; 42(3): 145-158.",
+          "source_type": "journal",
+          "completion_status": "complete"
+        },
+        {
+          "reference_id": "pm_claim_2_1",
+          "formatted_citation": "Clinical Research Team et al. Efficacy of daratumumab in multiple myeloma treatment. Blood Cancer J [Internet]. 2024 Mar 15 [cited 2024 Nov 15]; 14(1): 25. Available from: https://doi.org/10.1038/example",
+          "source_type": "journal", 
+          "completion_status": "complete"
+        }
+      ]
+    }
+  },
+  "summary_statistics": {
+    "document_metadata": {
+      "product": "daratumumab",
+      "countries": ["mexico", "brazil", "argentina"],
+      "language": "english"
+    },
+    "claims_analysis": {
+      "total_claims": 3,
+      "core_claims_count": 2
+    },
+    "claims_anchoring": {
+      "summary": {
+        "total_claims_processed": 2,
+        "successfully_validated": 2,
+        "validation_rate": 1.0,
+        "claims_summary": [
+          {
+            "claim_id": "claim_1",
+            "status": "validated",
+            "references_found": 1
+          },
+          {
+            "claim_id": "claim_2", 
+            "status": "validated",
+            "references_found": 1
+          }
+        ]
+      }
+    },
+    "reference_formatting": {
+      "total_references": 2
+    },
+    "processing_status": {
+      "analyzer": "completed",
+      "claim_claim_1": "completed",
+      "claim_claim_2": "completed"
+    }
+  }
+}
+```
+
+### 🔍 Estructura de la Respuesta:
+
+#### `detailed_analysis` (Contenido Principal):
+- **`claims_extracted`**: Claims identificados y clasificados por importancia
+- **`anchoring_results`**: Validación de evidencia para cada claim con referencias
+- **`formatted_references`**: Referencias formateadas según guidelines J&J
+
+#### `summary_statistics` (Información Resumida):
+- **`document_metadata`**: Producto, países, idioma detectados
+- **`claims_analysis`**: Conteos y métricas de claims
+- **`claims_anchoring`**: Tasa de validación y resumen
+- **`reference_formatting`**: Total de referencias procesadas
+- **`processing_status`**: Estado de procesamiento por agente
 
 ### 1. Análisis de Documento (Analyzer Agent)
 - Extrae claims y los clasifica por importancia

app.py

@@ -643,20 +643,7 @@ def get_base_html(active_section: str = "ai-generator", question_value: str = ""
                     {research_response}
                 </div>
                 
-                <!-- API Information -->
-                <div class="api-info">
-                    <h3>🔗 Available API Endpoints</h3>
-                    <ul>
-                        <li><strong>GET /</strong> - This HTML interface</li>
-                        <li><strong>GET /docs</strong> - Interactive API documentation</li>
-                        <li><strong>GET /api/hello</strong> - JSON greeting message</li>
-                        <li><strong>GET /api/health</strong> - Application health check</li>
-                        <li><strong>POST /ask</strong> - AI question answering (form)</li>
-                        <li><strong>POST /process</strong> - Document processing (form)</li>
-                        <li><strong>POST /api/generate</strong> - AI question answering (JSON API)</li>
-                        <li><strong>POST /api/research/process</strong> - Document processing (JSON API)</li>
-                    </ul>
-                </div>
+                
             </div>
         </div>
     </body>